Literature DB >> 10103206

Alterations in GyrA and ParC associated with fluoroquinolone resistance in Enterococcus faecium.

N A el Amin1, S Jalal, B Wretlind.   

Abstract

High-level quinolone resistance in Enterococcus faecium was associated with mutations in both gyrA and parC genes in 10 of 11 resistant strains. On low-level resistant strain without such mutations may instead possess an efflux mechanism or alterations in the other subunits of the gyrase or topoisomerase IV genes. These findings are similar to those for other gram-positive bacteria, such as Enterococcus faecalis.

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10103206      PMCID： PMC89232     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  30 in total

Review 1.  Mechanism of quinolone uptake into bacterial cells.

Authors:  L J Piddock
Journal:  J Antimicrob Chemother       Date:  1991-04       Impact factor: 5.790

2.  4-Quinolone resistance mutations in the DNA gyrase of Escherichia coli clinical isolates identified by using the polymerase chain reaction.

Authors:  M Oram; L M Fisher
Journal:  Antimicrob Agents Chemother       Date:  1991-02       Impact factor: 5.191

3.  Antibiotic sensitivity testing. Report of an international collaborative study.

Authors:  H M Ericsson; J C Sherris
Journal:  Acta Pathol Microbiol Scand B Microbiol Immunol       Date:  1971

4.  Nucleotide sequence and characterization of the Staphylococcus aureus norA gene, which confers resistance to quinolones.

Authors:  H Yoshida; M Bogaki; S Nakamura; K Ubukata; M Konno
Journal:  J Bacteriol       Date:  1990-12       Impact factor: 3.490

5.  Proportion of DNA gyrase mutants among quinolone-resistant strains of Pseudomonas aeruginosa.

Authors:  H Yoshida; M Nakamura; M Bogaki; S Nakamura
Journal:  Antimicrob Agents Chemother       Date:  1990-06       Impact factor: 5.191

6.  Targeting of DNA gyrase in Streptococcus pneumoniae by sparfloxacin: selective targeting of gyrase or topoisomerase IV by quinolones.

Authors:  X S Pan; L M Fisher
Journal:  Antimicrob Agents Chemother       Date:  1997-02       Impact factor: 5.191

7.  Ciprofloxacin resistance in clinical isolates of Salmonella typhimurium obtained from two patients.

Authors:  L J Piddock; D J Griggs; M C Hall; Y F Jin
Journal:  Antimicrob Agents Chemother       Date:  1993-04       Impact factor: 5.191

8.  Mechanism of action of quinolones against Escherichia coli DNA gyrase.

Authors:  H Yoshida; M Nakamura; M Bogaki; H Ito; T Kojima; H Hattori; S Nakamura
Journal:  Antimicrob Agents Chemother       Date:  1993-04       Impact factor: 5.191

9.  Mutations in the gyrA gene of a highly fluoroquinolone-resistant clinical isolate of Escherichia coli.

Authors:  P Heisig; H Schedletzky; H Falkenstein-Paul
Journal:  Antimicrob Agents Chemother       Date:  1993-04       Impact factor: 5.191

10.  Efflux-mediated fluoroquinolone resistance in Staphylococcus aureus.

Authors:  G W Kaatz; S M Seo; C A Ruble
Journal:  Antimicrob Agents Chemother       Date:  1993-05       Impact factor: 5.191
View more
  17 in total

1.  In vitro development of resistance to six quinolones in Streptococcus pneumoniae, Streptococcus pyogenes, and Staphylococcus aureus.

Authors:  M Boos; S Mayer; A Fischer; K Köhrer; S Scheuring; P Heisig; J Verhoef; A C Fluit; F J Schmitz
Journal:  Antimicrob Agents Chemother       Date:  2001-03       Impact factor: 5.191

2.  First characterization of fluoroquinolone resistance in Streptococcus suis.

Authors:  Jose Antonio Escudero; Alvaro San Millan; Ana Catalan; Adela G de la Campa; Estefania Rivero; Gema Lopez; Lucas Dominguez; Miguel Angel Moreno; Bruno Gonzalez-Zorn
Journal:  Antimicrob Agents Chemother       Date:  2006-11-20       Impact factor: 5.191

3.  Multistep resistance development studies of ceftaroline in gram-positive and -negative bacteria.

Authors:  Catherine Clark; Pamela McGhee; Peter C Appelbaum; Klaudia Kosowska-Shick
Journal:  Antimicrob Agents Chemother       Date:  2011-02-22       Impact factor: 5.191

4.  gyrA mutations associated with quinolone resistance in Bacteroides fragilis group strains.

Authors:  H Oh; N El Amin; T Davies; P C Appelbaum; C Edlund
Journal:  Antimicrob Agents Chemother       Date:  2001-07       Impact factor: 5.191

5.  In vitro activity of trovafloxacin against Bacteroides fragilis in mixed culture with either Escherichia coli or a vancomycin- resistant strain of Enterococcus faecium determined by an anaerobic time-kill technique.

Authors:  L E Stearne; C Kooi; W H Goessens; I A Bakker-Woudenberg; I C Gyssens
Journal:  Antimicrob Agents Chemother       Date:  2001-01       Impact factor: 5.191

Review 6.  The Enterococcus: a Model of Adaptability to Its Environment.

Authors:  Mónica García-Solache; Louis B Rice
Journal:  Clin Microbiol Rev       Date:  2019-01-30       Impact factor: 26.132

7.  In vitro activities of garenoxacin (BMS-284756) against Streptococcus pneumoniae, viridans group streptococci, and Enterococcus faecalis compared to those of six other quinolones.

Authors:  Patrick Grohs; Serge Houssaye; Agnès Aubert; Laurent Gutmann; Emmanuelle Varon
Journal:  Antimicrob Agents Chemother       Date:  2003-11       Impact factor: 5.191

8.  Comparison of mismatch amplification mutation assay with DNA sequencing for characterization of fluoroquinolone resistance in Neisseria gonorrhoeae.

Authors:  Zafar Sultan; Shamsun Nahar; Bengt Wretlind; Emma Lindback; Motiur Rahman
Journal:  J Clin Microbiol       Date:  2004-02       Impact factor: 5.948

9.  High-level ciprofloxacin resistance from point mutations in gyrA and parC confined to global hospital-adapted clonal lineage CC17 of Enterococcus faecium.

Authors:  Helen L Leavis; Rob J L Willems; Janetta Top; Marc J M Bonten
Journal:  J Clin Microbiol       Date:  2006-03       Impact factor: 5.948

10.  High abundance and diversity of antimicrobial resistance determinants among early vancomycin-resistant Enterococcus faecium in Poland.

Authors:  E Sadowy; A Sieńko; I Gawryszewska; A Bojarska; K Malinowska; W Hryniewicz
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2013-04-05       Impact factor: 3.267
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.